수혈 진단 시장 : 제품별, 기술별, 용도별, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Blood Transfusion Diagnostics Market is projected to grow by USD 6.03 billion at a CAGR of 5.19% by 2032.

Blood Transfusion Diagnostics Market Introduction

Blood transfusion diagnostics is the testing backbone that makes transfusion therapy safe, traceable, and clinically effective. The field spans ABO and RhD blood grouping, extended antigen typing, antibody screening and identification, compatibility testing, direct antiglobulin testing, and transfusion-transmitted infection screening using serology, immunohematology automation, molecular assays, and nucleic acid testing.

Demand is supported by surgery, oncology, trauma care, obstetrics, chronic anemia management, transplantation, and aging populations. According to the World Health Organization, more than 118 million blood donations are collected globally each year, yet access and testing capacity remain uneven across income groups and health systems. This creates a sustained need for reliable blood bank diagnostics, standardized quality systems, and scalable platforms that improve turnaround time without compromising patient safety.

Transformative Shifts in Blood Transfusion Diagnostics

The blood transfusion diagnostics landscape is shifting from manual, batch-based testing toward integrated, automated, and data-connected workflows. Blood centers and hospital transfusion services are prioritizing high-throughput immunohematology analyzers, automated crossmatching, electronic blood management systems, and molecular typing to reduce human error, strengthen traceability, and support complex patient populations.

Regulatory expectations are also reshaping adoption. Authorities in major markets require validated infectious disease screening, donor traceability, quality controls, and hemovigilance reporting. At the same time, demand for phenotype- and genotype-matched blood is increasing for patients with sickle cell disease, thalassemia, cancer, transplantation needs, and prior alloimmunization, moving diagnostics from basic compatibility testing to precision transfusion support.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to improve transfusion diagnostics through image interpretation, antibody identification support, predictive inventory management, and risk stratification for adverse transfusion reactions. AI-enabled decision support can help laboratories prioritize complex cases, detect testing inconsistencies, and forecast component demand based on procedure schedules, trauma patterns, historical utilization, and seasonal blood collection pressures.

The cumulative impact is operational as much as clinical. AI can reduce avoidable wastage, improve blood availability, and support standardized interpretation across decentralized networks. However, adoption depends on validated datasets, explainable models, cybersecurity, interoperability with laboratory information systems, and regulatory oversight to ensure that algorithmic recommendations strengthen, rather than replace, expert transfusion medicine judgment.

Key Regional Insights

Asia-Pacific is becoming a high-priority region as China, India, Japan, South Korea, and Australia expand hospital networks, cancer care, transplant programs, trauma systems, and national blood safety initiatives. The region's scale creates strong demand for automated blood grouping, infectious disease screening, and molecular testing, while rural access gaps continue to support decentralized, cost-efficient diagnostics and training-backed quality programs.

North America and Europe remain advanced adoption centers due to mature blood bank infrastructure, stringent regulatory frameworks, broad use of automation, accreditation-driven quality systems, and established hemovigilance practices. Latin America is improving screening quality through public blood programs and private diagnostic investment, with Brazil and Mexico playing central roles in regional blood service modernization. The Middle East is supported by hospital modernization, tertiary care expansion, and GCC healthcare investment, while Africa's opportunity is tied to strengthening voluntary donation systems, donor screening, cold-chain reliability, and access to standardized testing for transfusion-transmitted infections.

Key Group Insights

ASEAN demand is shaped by population growth, expanding universal health coverage, and modernization of hospital laboratories across Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines. Adoption varies widely across the group, making scalable, service-backed platforms important for both centralized blood centers and decentralized hospital transfusion services. GCC countries are investing in tertiary hospitals, trauma centers, medical tourism, and digital health infrastructure, strengthening demand for automated transfusion testing, donor screening, and connected blood bank information systems.

The European Union benefits from harmonized quality expectations, advanced immunohematology practices, and cross-border standards for blood safety, including strong attention to traceability and hemovigilance. BRICS countries combine large patient bases with rapidly expanding diagnostic infrastructure, particularly in China, India, and Brazil, where surgical volumes, chronic disease care, and public health investment support broader testing needs. G7 markets lead in premium automation, molecular typing, quality assurance, and AI-enabled workflow optimization, while NATO countries place additional emphasis on emergency preparedness, blood supply resilience, and interoperability across military and civilian medical systems.

Key Country Insights

The United States leads in advanced immunohematology automation, molecular blood typing, electronic crossmatch adoption, and transfusion-transmitted infection screening, supported by FDA-regulated blood safety requirements, accreditation systems, and large hospital networks. Canada emphasizes national blood system coordination, quality standardization, and equitable access across geographically dispersed populations, while Mexico and Brazil continue to upgrade donor screening, infectious disease testing, and regional blood bank networks to improve transfusion safety and availability.

In Europe, the United Kingdom, Germany, France, Italy, and Spain rely on mature transfusion services, strong quality systems, established hemovigilance practices, and rising demand for matched blood in oncology, hematology, surgery, and chronic disease care. Russia maintains substantial public blood infrastructure with continued relevance for hospital-based transfusion support. China and India represent major growth engines because of population scale, surgical volume, cancer treatment expansion, maternal health needs, and increasing laboratory capacity. Japan, South Korea, and Australia show high automation uptake, quality control maturity, digital workflow integration, and strong clinical demand for precision transfusion practices.

Actionable Recommendations for Industry Leaders

Vendors should prioritize platforms that combine immunohematology automation, infectious disease screening, molecular typing, and digital connectivity. Product strategies should address both high-throughput reference laboratories and decentralized hospital blood banks, with flexible reagent menus, reliable service coverage, quality control support, and validation assistance tailored to local regulatory needs.

Commercial success will depend on partnerships with blood services, hospital networks, public health agencies, and laboratory information system vendors. Industry leaders should invest in AI-ready data architecture, cybersecurity, staff training, interoperability, and post-implementation evidence generation. In emerging markets, value-based models, reagent rental programs, remote support, and technical education can accelerate adoption while supporting sustainable blood safety improvements.

Research Methodology

The research methodology is developed through secondary research using publicly available and institutionally recognized sources, including the World Health Organization, national blood services, health authorities, regulatory agencies, peer-reviewed transfusion medicine literature, and standards organizations. The analysis considers donor collection patterns, transfusion safety requirements, technology adoption, healthcare infrastructure, clinical demand drivers, and regional disease burdens.

The methodology applies cross-validation across multiple source categories to avoid reliance on a single dataset. Qualitative industry signals are evaluated alongside documented clinical practices, regulatory requirements, and technology trends in blood grouping, compatibility testing, infectious disease screening, molecular diagnostics, automation, hemovigilance, and digital workflow management.

Conclusion

Blood transfusion diagnostics is moving from a compliance-centered testing function to a strategic enabler of safer, faster, and more personalized transfusion care. Automation, molecular typing, AI-enabled analytics, and connected laboratory systems are redefining how blood banks manage compatibility, safety, inventory, traceability, and clinical risk.

The strongest opportunities will emerge where proven diagnostic accuracy is paired with scalable service models, regulatory readiness, workforce enablement, and digital interoperability. Organizations that align product innovation with blood safety priorities, laboratory capacity constraints, and regional access needs will be best positioned to lead the next phase of the blood transfusion diagnostics market.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Blood Transfusion Diagnostics Market, by Product

• 7.1. Consumables & Accessories
  • 7.1.1. Microplates
  • 7.1.2. Pipette Tips
• 7.2. Instruments
  • 7.2.1. NAT Analyzers
  • 7.2.2. Pathogen Reduction Systems
  • 7.2.3. Serology Analyzers
• 7.3. Reagents & Kits
  • 7.3.1. Amplification Reagents
  • 7.3.2. Antibody Reagents
  • 7.3.3. DNA Extraction Kits

8. Blood Transfusion Diagnostics Market, by Technology

• 8.1. Nucleic Acid Testing
  • 8.1.1. PCR
  • 8.1.2. Transcription Mediated Amplification
• 8.2. Pathogen Reduction Technology
  • 8.2.1. Amotosalen
  • 8.2.2. Methylene Blue
  • 8.2.3. Riboflavin
• 8.3. Serological Testing
  • 8.3.1. ELISA
  • 8.3.2. Lateral Flow Assays

9. Blood Transfusion Diagnostics Market, by Application

• 9.1. Donation Screening
  • 9.1.1. Immunohematology Testing
  • 9.1.2. Viral Marker Screening
• 9.2. Quality Control
  • 9.2.1. External Proficiency Testing
  • 9.2.2. Internal Quality Control
• 9.3. Transfusion Safety
  • 9.3.1. Blood Group Typing
  • 9.3.2. Pathogen Inactivation

10. Blood Transfusion Diagnostics Market, by End User

• 10.1. Hospital Blood Banks
• 10.2. Independent Laboratories
• 10.3. Research Institutes

11. Blood Transfusion Diagnostics Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Blood Transfusion Diagnostics Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Blood Transfusion Diagnostics Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Abbott Laboratories
• 15.2. Agena Bioscience, Inc.
• 15.3. BAG Health Care GmbH
• 15.4. Becton, Dickinson and Company
• 15.5. Bio-Rad Laboratories, Inc.
• 15.6. bioMerieux SA
• 15.7. Danaher Corporation
• 15.8. DIAGAST S.A.S.
• 15.9. DiaSorin S.p.A.
• 15.10. F. Hoffmann-La Roche Ltd
• 15.11. Fresenius Kabi AG
• 15.12. Grifols, S.A.
• 15.13. Hema Bioscience Inc.
• 15.14. HemoCue AB
• 15.15. Hologic, Inc.
• 15.16. Immucor, Inc.
• 15.17. Inno-Train Diagnostik GmbH
• 15.18. Ortho Clinical Diagnostics, Inc.
• 15.19. Quotient Limited
• 15.20. Siemens Healthineers AG
• 15.21. Sysmex Corporation
• 15.22. Thermo Fisher Scientific Inc.
• 15.23. Tulip Diagnostics (P) Ltd.
• 15.24. Werfen S.A.